

20 November 2012 EMA/HMPC/524621/2011 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on *Levisticum officinale* Koch, radix

Final

Discussion in Working Party on Community monographs and Community	July 2011
list (MLWP)	September 2011
	November 2011
	January 2012
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	27 March 2012
for consultation	27 March 2012
End of consultation (deadline for comments).	15 August 2012
Rediscussion in Working Party on Community monographs and	September 2012
Community list (MLWP)	September 2012
Adoption by Committee on Herbal Medicinal Products (HMPC)	20 November 2012

KeywordsHerbal medicinal products; HMPC; Community herbal monographs; traditional
use; Levisticum officinale Koch, radix; Levistici radix; Lovage root

BG (bălgarski): Селим, корен	LT (lietuvių kalba): Gelsvių šaknys
CS (čeština): Libečkový kořen	LV (latviešu valoda): Lupstāja saknes
DA (dansk): Løvstikkerod	MT (malti): Gherq tal-Levistiku
DE (Deutsch): Liebstöckelwurzel	NL (nederlands): Lavaswortel
EL (elliniká): Ρίζα λυγιστικού	PL (polski): Korzeń lubczyka
EN (English): Lovage root	PT (português): Levístico, raiz
ES (espanol): Levístico, raíz de	RO (română):
ET (eesti keel): Leeskputkejuur	SK (slovenčina): Ligurčekový koreň
FI (suomi): Liperi, juuri	SL (slovenščina): Korenina luštreka
FR (français): Livèche (racine de)	SV (svenska): Libbstickerot
HU (magyar): Lestyángyökér	IS (íslenska):
IT (italiano): Levistico radice	NO (norsk): Løpestikkerot

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail info@ema.europa.eu Website www.ema.europa.eu



An agency of the European Union

© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

Community herbal monograph on Levisticum officinale Koch, radix

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1,2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Levisticum officinale Koch, radix (lovage root)
	i) Herbal substance
	Not applicable.
	ii) Herbal preparations
	Comminuted herbal substance

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for oral use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product used to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints.

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance. 2 The material complies with the Ph. Eur. monograph (ref.: 01/2013:1233).

Well-established use	Traditional use
	Posology
	Adults and elderly
	Herbal tea
	Single dose: 2 - 3 g of comminuted herbal substance in 150 ml of boiling water as a herbal infusion, twice daily.
	Average daily dose: 4 - 6 g
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	Not to be used for more than 2 - 4 weeks.
	If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.

4.2. Posology and method of administration³

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance and to other plants of the Apiaceae (Umbelliferae) family or to anethole.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	 The use in children and adolescents under 18 years of age is not recommended because of concerns requiring medical advice. If complaints or symptoms such as fever, dysuria, spasms, or blood in urine occur during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

³ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	No fertility data available.
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	None known.
	If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision

20 November 2012